Insider Selling: Cerus Co. (NASDAQ:CERS) SVP Sells 26,684 Shares of Stock

Cerus Co. (NASDAQ:CERS) SVP Carol Moore sold 26,684 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.59, for a total transaction of $95,795.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ:CERS traded up $0.43 during trading on Thursday, reaching $4.47. The company had a trading volume of 837,382 shares, compared to its average volume of 2,274,683. The company has a fifty day moving average of $4.66 and a two-hundred day moving average of $4.51. The stock has a market capitalization of $624.34 million, a P/E ratio of -8.60 and a beta of 1.19. Cerus Co. has a 12 month low of $2.71 and a 12 month high of $6.64. The company has a current ratio of 2.55, a quick ratio of 2.16 and a debt-to-equity ratio of 1.01.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.01). The company had revenue of $20.92 million during the quarter, compared to the consensus estimate of $20.90 million. Cerus had a negative return on equity of 112.64% and a negative net margin of 95.44%. As a group, equities research analysts predict that Cerus Co. will post -0.44 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. grew its holdings in shares of Cerus by 23.7% during the 4th quarter. Macquarie Group Ltd. now owns 245,368 shares of the biotechnology company’s stock valued at $1,035,000 after purchasing an additional 47,046 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Cerus by 35.1% during the 4th quarter. Nuveen Asset Management LLC now owns 892,290 shares of the biotechnology company’s stock valued at $3,765,000 after purchasing an additional 231,849 shares during the last quarter. Norges Bank bought a new position in shares of Cerus during the 4th quarter valued at $5,248,000. Geode Capital Management LLC grew its holdings in shares of Cerus by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 1,902,399 shares of the biotechnology company’s stock valued at $8,028,000 after purchasing an additional 57,697 shares during the last quarter. Finally, CVA Family Office LLC bought a new position in shares of Cerus during the 4th quarter valued at $42,000. 69.56% of the stock is currently owned by institutional investors.

CERS has been the topic of a number of research analyst reports. BTIG Research initiated coverage on shares of Cerus in a report on Wednesday, February 26th. They issued a “buy” rating and a $7.00 price target on the stock. BidaskClub lowered shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a report on Wednesday, March 18th. Finally, ValuEngine raised shares of Cerus from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $7.33.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: What are high-yield dividend stocks?

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.